论文部分内容阅读
15例肝癌患者施行外科治疗,12例兼用卡介苗、混合菌苗及干扰素,3例不用免疫治疗为对照。分离患者血单核细胞(MC)与淋巴细胞(LC)及肝枯否细胞(KC),以人肝癌细胞株为靶细胞(TC)。结果:①首次用免疫制剂7d后,MC对TC抑增殖作用及杀伤作用明显高于用药前,3次用药后MC抑TC效应提高至84％,对照组的仍为45％;②首次用药后7d,KC对TC的抑增殖率和杀伤率分别较对照组高0.5倍和1倍;③用免疫制剂后,血T细胞总数及Th数持续升高,T_s则显著下降。研究表明三联免疫制剂可有效地增强患者抗肝癌细胞的免疫功能。
15 cases of liver cancer patients were treated with surgery, 12 cases were treated with BCG, mixed bacterins and interferon, and 3 cases were not treated with immunotherapy. Blood mononuclear cells (MC) and lymphocytes (LC) and hepatic Kupffer cells (KC) were isolated from patients, and human hepatoma cell lines were used as target cells (TC). RESULTS: 1After 7 days of immunosuppression for the first time, MC inhibited the proliferation and killing effects of TC significantly higher than before administration. After 3 administrations, the TC effect of MC increased to 84%, while that of the control group remained at 45%; 2 after the first administration 7d, KC TC inhibition rate of proliferation and killing rate were 0.5 times and 1 times higher than the control group; 3 after the use of immunizing agents, the total number of T-cell counts and Th continue to increase, T_s decreased significantly. Studies have shown that triple immunosuppressive agents can effectively enhance the immune function of patients with anti-hepatoma cells.